Patents Assigned to Novocure Ltd.
  • Patent number: 8706261
    Abstract: Cells that are in the late anaphase or telophase stages of cell division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like tumor cells, but does not harm normal cells that are not dividing. Improved results may be achieved by using a field with two or more frequencies.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: April 22, 2014
    Assignee: Novocure Ltd.
    Inventor: Yoram Palti
  • Patent number: 8447396
    Abstract: Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: May 21, 2013
    Assignee: Novocure Ltd.
    Inventors: Yoram Palti, Moshe Giladi
  • Patent number: 8406870
    Abstract: Chemotherapeutic treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to a particular type of target cell. When the tuned fields were combined with Paclitaxel, Doxorubicin or Cyclophosphamide, excellent results were obtained against human breast cancer cells (MDA-MB-231) and non-small cell lung (H1299) carcinomas in culture. More specifically, cell proliferation inhibition similar to that obtained by drug alone was reached by exposure to the combined treatment at drug concentrations between one and two orders of magnitude lower than for drug-only regimens of treatment.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: March 26, 2013
    Assignee: Novocure Ltd.
    Inventor: Yoram Palti
  • Patent number: 8229555
    Abstract: An article of clothing is provided for selectively destroying dividing cells in living tissue formed of dividing cells and non-dividing cells. The dividing cells contain polarizable intracellular members and during late anaphase or telophase, the dividing cells are connected to one another by a cleavage furrow. The article of clothing includes insulated electrodes to be coupled to a generator for subjecting the living tissue to electric field conditions sufficient to cause movement of the polarizable intracellular members toward the cleavage furrow in response to a non-homogeneous electric field being induced in the dividing cells. The non-homogeneous electric field produces an increased density electric field in the region of the cleavage furrow. The movement of the polarizable intracellular members towards the cleavage furrow causes the breakdown thereof which adversely impacts the multiplication of the dividing cells.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: July 24, 2012
    Assignee: Novocure Ltd.
    Inventor: Yoram Palti
  • Patent number: 8175698
    Abstract: Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: May 8, 2012
    Assignee: Novocure Ltd.
    Inventors: Yoram Palti, Moshe Giladi
  • Patent number: 8019414
    Abstract: Chemotherapeutic treatment for certain cancers may be combined with low intensity, intermediate frequency alternating electric fields that are tuned to a particular type of target cell. When the tuned fields were combined with Paclitaxel, Doxorubicin or Cyclophosphamide, excellent results were obtained against human breast cancer cells (MDA-MB-231) and non-small cell lung (H1299) carcinomas in culture. More specifically, cell proliferation inhibition similar to that obtained by drug alone was reached by exposure to the combined treatment at drug concentrations between one and two orders of magnitude lower than for drug-only regimens of treatment.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: September 13, 2011
    Assignee: Novocure Ltd.
    Inventor: Yoram Palti
  • Patent number: 7890183
    Abstract: Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective disruption of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages or disrupts rapidly dividing cells like parasites, but does not harm normal cells that are not dividing.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: February 15, 2011
    Assignee: Novocure Ltd.
    Inventors: Yoram Palti, Moshe Giladi